Guggenheim started coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a research report report published on Thursday, MarketBeat Ratings reports. The brokerage issued a neutral rating on the biotechnology company’s stock.
Other research analysts have also issued research reports about the stock. BidaskClub raised shares of Atara Biotherapeutics from a hold rating to a buy rating in a research note on Thursday, January 11th. Canaccord Genuity reaffirmed a buy rating on shares of Atara Biotherapeutics in a research note on Friday, December 29th. Jefferies Group increased their target price on shares of Atara Biotherapeutics from $30.00 to $46.00 and gave the stock a buy rating in a research note on Monday, March 5th. Zacks Investment Research raised shares of Atara Biotherapeutics from a sell rating to a hold rating in a research note on Thursday, February 15th. Finally, ValuEngine raised shares of Atara Biotherapeutics from a sell rating to a hold rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of $33.80.
Atara Biotherapeutics (ATRA) opened at $41.90 on Thursday. Atara Biotherapeutics has a 12 month low of $11.80 and a 12 month high of $49.90.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Pacific Heights Asset Management LLC purchased a new position in shares of Atara Biotherapeutics in the fourth quarter valued at approximately $453,000. Artal Group S.A. lifted its stake in Atara Biotherapeutics by 66.7% in the fourth quarter. Artal Group S.A. now owns 1,000,000 shares of the biotechnology company’s stock worth $18,100,000 after acquiring an additional 400,000 shares during the last quarter. Perceptive Advisors LLC purchased a new position in Atara Biotherapeutics in the third quarter worth approximately $581,000. Nexthera Capital LP purchased a new position in Atara Biotherapeutics in the fourth quarter worth approximately $5,188,000. Finally, Neuberger Berman Group LLC lifted its stake in Atara Biotherapeutics by 15.2% in the third quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock worth $18,454,000 after acquiring an additional 147,061 shares during the last quarter. 76.88% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Atara Biotherapeutics (ATRA) Research Coverage Started at Guggenheim” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3274959/atara-biotherapeutics-atra-research-coverage-started-at-guggenheim.html.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.